Published in Cardiovasc Res on July 01, 1998
Cytosolic Ca2+ triggers early afterdepolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome. J Physiol (2002) 2.47
Clinical and genetic determinants of torsade de pointes risk. Circulation (2012) 1.67
Sex, age, and regional differences in L-type calcium current are important determinants of arrhythmia phenotype in rabbit hearts with drug-induced long QT type 2. Circ Res (2008) 1.30
Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br J Pharmacol (2008) 1.28
Altered potassium balance and aldosterone secretion in a mouse model of human congenital long QT syndrome. Proc Natl Acad Sci U S A (2001) 1.16
The contribution of refractoriness to arrhythmic substrate in hypokalemic Langendorff-perfused murine hearts. Pflugers Arch (2007) 1.10
Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes. Br J Pharmacol (2002) 1.05
Pharmacological separation of early afterdepolarizations from arrhythmogenic substrate in DeltaKPQ Scn5a murine hearts modelling human long QT 3 syndrome. Acta Physiol (Oxf) (2007) 0.99
In vitro models of proarrhythmia. Br J Pharmacol (2008) 0.95
Blockade of I(Ca) suppresses early afterdepolarizations and reduces transmural dispersion of repolarization in a whole heart model of chronic heart failure. Br J Pharmacol (2012) 0.92
Comprehensive analyses of ventricular myocyte models identify targets exhibiting favorable rate dependence. PLoS Comput Biol (2014) 0.91
Triple threat: the Na+/Ca2+ exchanger in the pathophysiology of cardiac arrhythmia, ischemia and heart failure. Curr Drug Targets (2011) 0.90
Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol (2015) 0.90
Differences in action potential and early afterdepolarization properties in LQT2 and LQT3 models of long QT syndrome. Br J Pharmacol (2001) 0.89
Separation of early afterdepolarizations from arrhythmogenic substrate in the isolated perfused hypokalaemic murine heart through modifiers of calcium homeostasis. Acta Physiol (Oxf) (2007) 0.86
Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence. Br J Pharmacol (2001) 0.82
The significance of bradycardia in anorexia nervosa. Int J Angiol (2013) 0.79
Recapitulating long-QT syndrome using induced pluripotent stem cell technology. Pediatr Cardiol (2012) 0.77
The link between abnormal calcium handling and electrical instability in acquired long QT syndrome - Does calcium precipitate arrhythmic storms? Prog Biophys Mol Biol (2015) 0.75
Severe proarrhythmic potential of risperidone compared to quetiapine in an experimental whole-heart model of proarrhythmia. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Murine Electrophysiological Models of Cardiac Arrhythmogenesis. Physiol Rev (2017) 0.75
Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation (2001) 7.47
Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature (1998) 7.26
Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J (2002) 3.01
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. Circulation (2010) 2.53
Post-infarction depression and incomplete recovery 6 months after acute myocardial infarction. Lancet (1994) 2.39
xIAP induces cell-cycle arrest and activates nuclear factor-kappaB : new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ Res (2001) 2.10
Clinical evaluation of no-carrier-added meta-[123I]iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med (2000) 2.06
A prognostic computer model to individually predict post-procedural complications in interventional cardiology: the INTERVENT Project. Eur Heart J (1999) 1.98
The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J (2000) 1.92
KCNE1 mutations cause jervell and Lange-Nielsen syndrome. Nat Genet (1997) 1.90
De novo mutation in the SCN5A gene associated with early onset of sudden infant death. Circulation (2001) 1.88
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia (2013) 1.77
Incidence and clinical significance of left ventricular thrombus in tako-tsubo cardiomyopathy assessed with echocardiography. QJM (2008) 1.71
Targeting the slow pathway for atrioventricular nodal reentrant tachycardia: initial results and long-term follow-up in 379 consecutive patients. Eur Heart J (2001) 1.71
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res (2000) 1.70
Molecular diagnosis in a child with sudden infant death syndrome. Lancet (2001) 1.66
Predictors of in-hospital mortality after DC catheter ablation of atrioventricular junction. Results of a prospective, international, multicenter study. Circulation (1991) 1.64
Standards for analysis of ventricular late potentials using high-resolution or signal-averaged electrocardiography: a statement by a task force committee of the European Society of Cardiology, the American Heart Association, and the American College of Cardiology. J Am Coll Cardiol (1991) 1.63
A prognostic computer model to predict individual outcome in interventional cardiology. The INTERVENT Project. Eur Heart J (1997) 1.61
Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation (1992) 1.61
An anatomically and electrogram-guided stepwise approach for effective and safe catheter ablation of the fast pathway for elimination of atrioventricular node reentrant tachycardia. J Am Coll Cardiol (1995) 1.61
[Inadequate therapies with implantable cardioverter-defibrillators--incidence, etiology, predictive factors and preventive strategies]. Z Kardiol (1996) 1.59
Gene-specific differences in the circadian variation of ventricular repolarization in the long QT syndrome: a key to sudden death during sleep? Ital Heart J (2000) 1.59
A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial. Clin Res Cardiol (2006) 1.59
A novel long-QT 5 gene mutation in the C-terminus (V109I) is associated with a mild phenotype. J Mol Med (Berl) (2001) 1.56
Erroneous discharge of an implantable cardioverter defibrillator caused by an electric razor. Pacing Clin Electrophysiol (1995) 1.54
Prevalence of coronary artery disease in a general population without suspicion of coronary artery disease: angiographic analysis of subjects aged 40 to 70 years referred for catheter ablation therapy. Eur Heart J (2000) 1.52
Intraoperative radiofrequency ablation of chronic atrial fibrillation: a left atrial curative approach by elimination of anatomic "anchor" reentrant circuits. J Cardiovasc Electrophysiol (1999) 1.52
Is there a need for routine testing of ICD defibrillation capacity? Results from more than 1000 studies. Eur Heart J (2000) 1.51
Extracardiac contributions to chest pain perception in patients 6 months after acute myocardial infarction. Am Heart J (1999) 1.50
Haemodynamic quantification of different provocation manoeuvres by simultaneous measurement of right and left atrial pressure: implications for the echocardiographic detection of persistent foramen ovale. Eur J Echocardiogr (2001) 1.47
Successful radiofrequency catheter ablation of right sided accessory pathways during sustained atrial fibrillation. Eur Heart J (1995) 1.47
Task Force Report: The legal implications of medical guidelines--a Task Force of the European Society of Cardiology. Eur Heart J (1999) 1.47
A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J (2001) 1.46
Diastolic filling pattern and left ventricular diameter predict response and prognosis after cardiac resynchronisation therapy. Heart (2007) 1.45
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation (1999) 1.44
Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J (1998) 1.44
Doppler echocardiographic assessment of the pressure gradient during bicycle ergometry in hypertrophic cardiomyopathy. Am J Cardiol (1992) 1.43
[18-year old patient with anti-epileptic therapy and sudden cardiac death]. Z Kardiol (2003) 1.41
The Percutaneous Cardiac Mapping and Ablation Registry: final summary of results. Pacing Clin Electrophysiol (1988) 1.39
Evaluation of antiarrhythmic drug efficacy in patients with an ICD: unlimited potential or replete with complexity and problems? J Cardiovasc Electrophysiol (1999) 1.39
Patients with valvular heart disease presenting with sustained ventricular tachyarrhythmias or syncope: results of programmed ventricular stimulation and long-term follow-up. Circulation (1997) 1.39
Temperature-controlled radiofrequency catheter ablation of manifest accessory pathways. Eur Heart J (1996) 1.39
Affective disorders and survival after acute myocardial infarction. Results from the post-infarction late potential study. Eur Heart J (1991) 1.39
[Diagnostic and therapeutic management of patients receiving antithrombotic drugs: what to heed?]. Dtsch Med Wochenschr (2006) 1.38
Contribution of heart rate variability to long-term risk stratification after myocardial infarction. Eur Heart J (1997) 1.38
Implantable cardioverter/defibrillators (ICD): a new lead-system using transvenous-subcutaneous approach in patients with prior cardiac surgery. Eur J Cardiothorac Surg (1991) 1.38
Effects of enflurane on inducibility of ventricular tachycardia. Am J Cardiol (1991) 1.38
Dynamics of mitral regurgitant flow and orifice area. Physiologic application of the proximal flow convergence method: clinical data and experimental testing. Circulation (1994) 1.38
ESCWGA/NASPE/P experts consensus statement: living anatomy of the atrioventricular junctions. A guide to electrophysiologic mapping. Working Group of Arrhythmias of the European Society of Cardiology. North American Society of Pacing and Electrophysiology. J Cardiovasc Electrophysiol (1999) 1.37
Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol (1999) 1.34
Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. Eur Heart J (1999) 1.29
Prognosis and possible presymptomatic manifestations of congestive cardiomyopathy (COCM). Postgrad Med J (1978) 1.28
Isolated noncompaction of the left ventricular myocardium -- a review of the literature two decades after the initial case description. Clin Res Cardiol (2007) 1.18
The LQT syndromes--current status of molecular mechanisms. Z Kardiol (1999) 1.18
Regional myocardial sympathetic dysinnervation in arrhythmogenic right ventricular cardiomyopathy. An analysis using 123I-meta-iodobenzylguanidine scintigraphy. Circulation (1994) 1.17
Potential benefit from implantable cardioverter-defibrillator therapy in patients with and without heart failure. Circulation (1998) 1.16
Prognostic significance of late ventricular potentials after acute myocardial infarction. Eur Heart J (1983) 1.15
Long QT syndrome and life threatening arrhythmia in a newborn: molecular diagnosis and treatment response. Heart (2004) 1.13
Aortic valve calcification: basic science to clinical practice. Heart (2008) 1.12